Cargando…

Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET

BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rokugawa, Takemi, Konishi, Haruyo, Ito, Miwa, Iimori, Hitoshi, Nagai, Ryohei, Shimosegawa, Eku, Hatazawa, Jun, Abe, Kohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981157/
https://www.ncbi.nlm.nih.gov/pubmed/29855729
http://dx.doi.org/10.1186/s13550-018-0394-4
_version_ 1783327987737821184
author Rokugawa, Takemi
Konishi, Haruyo
Ito, Miwa
Iimori, Hitoshi
Nagai, Ryohei
Shimosegawa, Eku
Hatazawa, Jun
Abe, Kohji
author_facet Rokugawa, Takemi
Konishi, Haruyo
Ito, Miwa
Iimori, Hitoshi
Nagai, Ryohei
Shimosegawa, Eku
Hatazawa, Jun
Abe, Kohji
author_sort Rokugawa, Takemi
collection PubMed
description BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of this study was to assess the potential of PET with (18)F-FPP-RGD(2) to detect hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mice. RESULTS: Thirty-two male C57BL/6 mice aged 6 weeks were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 3 and 8 weeks. (18)F-FPP-RGD(2) PET imaging of the liver was performed at 3 and 8 weeks after CDAHFD feeding. After PET scanning, levels of hepatic integrin αvβ, 3α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1(col1a1) were measured. Histopathological analysis of hepatic steatosis, inflammation, and fibrosis, as well as blood biochemistry analysis, was also performed. CDAHFD for 3 and 8 weeks produced a moderate-to-severe steatosis and inflammation of the liver in mice. NAFLD activity score (NAS) in mice fed the CDAHFD for 3 and 8 weeks were more than 4 indicating NASH or borderline NASH pathology. Fibrosis was observed only in mice fed the CDAHFD for 8 weeks. PET imaging showed that the hepatic standardized uptake value, SUV(80–90 min), was increased with prolonged CDAHFD feeding compared with the respective controls (CDAHFD 3 weeks 0.32 ± 0.06 vs 0.48 ± 0.05, p < 0.01; CDAHFD 8 weeks 0.35 ± 0.04 vs 0.75 ± 0.07, p < 0.01, respectively). Prolonged CDAHFD feeding increased hepatic mRNA and protein levels of integrin αv and β3 at 3 and 8 weeks. Hepatic (18)F-FPP-RGD(2) uptake and amount of integrin αv and β3 protein were well correlated (r = 0.593, p < 0.05 and r = 0.835, p < 0.001, respectively). Hepatic (18)F-FPP-RGD(2) uptake also showed a positive correlation with Sirius red-positive area. CONCLUSIONS: The hepatic uptake of (18)F-FPP-RGD(2) correlated well with integrin αv and β3 expression and histological fibrosis in a mouse model of NASH, suggesting the predictability of fibrosis in NASH pathology.
format Online
Article
Text
id pubmed-5981157
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59811572018-06-14 Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET Rokugawa, Takemi Konishi, Haruyo Ito, Miwa Iimori, Hitoshi Nagai, Ryohei Shimosegawa, Eku Hatazawa, Jun Abe, Kohji EJNMMI Res Original Research BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of this study was to assess the potential of PET with (18)F-FPP-RGD(2) to detect hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mice. RESULTS: Thirty-two male C57BL/6 mice aged 6 weeks were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 3 and 8 weeks. (18)F-FPP-RGD(2) PET imaging of the liver was performed at 3 and 8 weeks after CDAHFD feeding. After PET scanning, levels of hepatic integrin αvβ, 3α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1(col1a1) were measured. Histopathological analysis of hepatic steatosis, inflammation, and fibrosis, as well as blood biochemistry analysis, was also performed. CDAHFD for 3 and 8 weeks produced a moderate-to-severe steatosis and inflammation of the liver in mice. NAFLD activity score (NAS) in mice fed the CDAHFD for 3 and 8 weeks were more than 4 indicating NASH or borderline NASH pathology. Fibrosis was observed only in mice fed the CDAHFD for 8 weeks. PET imaging showed that the hepatic standardized uptake value, SUV(80–90 min), was increased with prolonged CDAHFD feeding compared with the respective controls (CDAHFD 3 weeks 0.32 ± 0.06 vs 0.48 ± 0.05, p < 0.01; CDAHFD 8 weeks 0.35 ± 0.04 vs 0.75 ± 0.07, p < 0.01, respectively). Prolonged CDAHFD feeding increased hepatic mRNA and protein levels of integrin αv and β3 at 3 and 8 weeks. Hepatic (18)F-FPP-RGD(2) uptake and amount of integrin αv and β3 protein were well correlated (r = 0.593, p < 0.05 and r = 0.835, p < 0.001, respectively). Hepatic (18)F-FPP-RGD(2) uptake also showed a positive correlation with Sirius red-positive area. CONCLUSIONS: The hepatic uptake of (18)F-FPP-RGD(2) correlated well with integrin αv and β3 expression and histological fibrosis in a mouse model of NASH, suggesting the predictability of fibrosis in NASH pathology. Springer Berlin Heidelberg 2018-05-31 /pmc/articles/PMC5981157/ /pubmed/29855729 http://dx.doi.org/10.1186/s13550-018-0394-4 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Rokugawa, Takemi
Konishi, Haruyo
Ito, Miwa
Iimori, Hitoshi
Nagai, Ryohei
Shimosegawa, Eku
Hatazawa, Jun
Abe, Kohji
Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title_full Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title_fullStr Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title_full_unstemmed Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title_short Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET
title_sort evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (nash) model mouse by (18)f-fpp-rgd(2) pet
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981157/
https://www.ncbi.nlm.nih.gov/pubmed/29855729
http://dx.doi.org/10.1186/s13550-018-0394-4
work_keys_str_mv AT rokugawatakemi evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT konishiharuyo evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT itomiwa evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT iimorihitoshi evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT nagairyohei evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT shimosegawaeku evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT hatazawajun evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet
AT abekohji evaluationofhepaticintegrinavb3expressioninnonalcoholicsteatohepatitisnashmodelmouseby18ffpprgd2pet